Quanta Brings Oxford Uni Money Man On Board
This article was originally published in Clinica
Advanced hemodialysis systems firm Quanta Fluid Solutions Ltd has appointed Giles Kerr non-executive director. Kerr is currently Chief Financial Officer at Oxford University and non-executive director at the university’s technology transfer arm, ISIS Innovation. He also serves on the board of specialist healthcare company BTG plc, where he is the firm’s Chairman of the Audit Committee and Senior Independent Director. Privately-held Quanta is currently commercializing its CE-marked SC+ portable, compact hemodialysis system; after raising £27m in a series B round in November last year, CEO John Milad had told Clinica that the next fundraising would likely be an IPO, and indicated at that time it could happen “12-18 months” from then.
You may also be interested in...
End-stage renal disease (ESRD) affects 600,000 Americans, striking over 120,000 people a year, and most of these patients require renal replacement therapy, such as hemodialysis. For most, that means a several-hour treatment, three times a week, at a dedicated outpatient center run by a service company like DaVita, Inc., or Fresenius Medical Care. But getting dialyzed at home is another option. Just under 2% of patients do home hemodialysis (HHD) today, but a growing number of companies are betting that this number could increase substantially.
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.